Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene versus fulvestrant in ESR1-mutant advanced ER-positive/HER2-negative breast cancer
2020-005936-31Phase 2Terminated
- Sponsor
- Sermonix Pharmaceuticals
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lasofoxifene in breast cancer (2 arms), sponsored by Sermonix Pharmaceuticals. Primary endpoint: Progression-Free Survival. Started Mar 2021; status: terminated.
02
Drugs
lasofoxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-005936-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005936-31.